ERBB2 and gastric cancer: HER2 serves as a key therapeutic target in GC, though its heterogeneity—evidenced by discordance rates of 45%–79% by immunohistochemistry (IHC) and 23%–54% by in situ hybridization (ISH) (2), —complicates patient stratification and precise targeting.